Loading
VEGFC (Vascular endothelial growth factor C) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.
Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates KDR/VEGFR2 and FLT4/VEGFR3 receptors.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Sunitinib.
In plain words · VEGFC (Vascular endothelial growth factor C) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.
VEGFC (Vascular endothelial growth factor C) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.
Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels.
No product in this corpus aims at VEGFC yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA VEGFC: RNA low tissue specificity; no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Hepatocellular carcinoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas VEGFC tissue; Open Targets ENSG00000150630 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Joukov et al, EMBO J, 1996, "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases". Source.
Sources: HGNC HGNC:12682 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P49767 (protein name, function text, keywords and locations (REST API)); CIViC gene VEGFC (1 evidence items, 0 assertions, 1 variants; diseases: Hepatocellular Carcinoma (GraphQL API, CC0))
Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates KDR/VEGFR2 and FLT4/VEGFR3 receptors. Location: Secreted (UniProt). Locus 4q34.3 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
No normal tissue stained high.
RNA cancer enhanced: Thyroid Carcinoma 36 pTPM.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"VEGFC" OR ABSTRACT:"VEGFC" OR TITLE:"vascular endothelial growth factor C" OR ABSTRACT:"vascular endothelial growth factor C" OR TITLE:"Vascular endothelial growth factor C" OR ABSTRACT:"Vascular endothelial growth factor C" OR TITLE:"VEGF-C" OR ABSTRACT:"VEGF-C") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VEGFC, not a curated reading list.